<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474927</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15010152</org_study_id>
    <nct_id>NCT02474927</nct_id>
  </id_info>
  <brief_title>Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation</brief_title>
  <official_title>Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John F. McDyer, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is a Phase II open label, single-arm pilot study to evaluate the safety
      and efficacy of combination therapy with carfilzomib, plasma exchange and intravenous
      immunoglobulins for AMR after lung transplantation and elucidate important clinical and
      immunologic phenotypes and mechanisms associated with these outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the proposed clinical investigation is to evaluate the effects of
      carfilzomib in addition to conventional therapy on short-term outcomes after the diagnosis of
      antibody-mediated rejection in lung transplant recipients. In this study, Carfilzomib will be
      administered at a dose of 20 mg/m2 on two consecutive days, each week for three weeks (Days 1
      2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be administered for
      1-2 complete cycles in the study. Patients will be followed for the duration of their
      hospital admission after enrollment. Post treatment follow-up will also occur on Days 42 and
      90.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Voluntarily suspended due to lack of study personnel
  </why_stopped>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in DSA strength, titer, and complement fixation</measure>
    <time_frame>Day 1 to Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in DSA strength, titer, and complement fixation</measure>
    <time_frame>Day 1 to Day 90 and Day 42 to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Day 1 to Day 42 and to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of pathologic changes consistent with AMR on transbronchial biopsy</measure>
    <time_frame>Day 1 to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient death attributable to AMR</measure>
    <time_frame>Day 1 to Day 90</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Non-lung irreversible end-organ failure</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse effects (AE)</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse effects (AE) requiring dose-modification</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hypogammaglobulinemia</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of culture-proven de novo infection</measure>
    <time_frame>Day 1 to Day 42</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diagnosis of systemic inflammatory response syndrome</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient death</measure>
    <time_frame>Day 1 to Day 90</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Carfilzomib Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib will be administered at a dose of 20 mg/m2 on two consecutive days, each week for three weeks (Days 1 2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be administered for 1-2 complete cycles in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)</description>
    <arm_group_label>Carfilzomib Treatment Arm</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult lung transplant recipients â‰¥ 18 years of age who meet the diagnostic criteria
             for AMR and who have underwent PFT testing unless intubated and transbronchial biopsy
             prior to enrollment.

        Exclusion Criteria:

          -  Direct contraindications or previous intolerances to any component of the standard of
             care regimen including PLEX, 5% human albumin, 5% gammagard S/D or 10% gammagard
             liquid

          -  Leukopenia

          -  Neutropenia

          -  Thrombocytopenia

          -  Known Child-Pugh B/C cirrhosis

          -  Total bilirubin &gt; 4

          -  ALT &gt; 90

          -  Known systolic heart failure with LVEF &lt; 40%

          -  Known pulmonary hypertension

          -  Any uncontrolled comorbid condition

          -  Pregnant women

          -  Breastfeeding women

          -  Ongoing bacterial or fungal or viral infection that is life-threatening

          -  Active cytomegalovirus disease

          -  Active varicella zoster infection

          -  Previous intolerance to carfilzomib

          -  Concurrent use of another proteasome inhibitor (e.g., bortezomib)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McDyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>John F. McDyer, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>antibody-mediated rejection</keyword>
  <keyword>lung transplant</keyword>
  <keyword>Carfilzomib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

